Skip to main content
. 2018 Oct 22;21(1):14–25. doi: 10.1093/neuonc/noy170

Fig. 4.

Fig. 4

Pooled proportion of survivors in recent virotherapies trials for rGBM at (A) 24 months and (B) 36 months. Studies on virotherapy clinical trials reporting 24-month and 36-month overall survival for rGBM are included. Survivors represent the number of patients surviving at 24 or 36 months. Total represents the total number of rGBM patients in a trial. Given the heterogeneity of designs, pooling of proportion of patients was performed via a random effects model.